Loading...
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
INTRODUCTION: As patients who receive cannabidiol (CBD) may have co-existing renal morbidities, it is important to understand whether dose adjustments are necessary to mitigate the risk of exposure-related toxicity. This study was conducted to evaluate the pharmacokinetics, safety, and tolerability...
Saved in:
| Published in: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292807/ https://ncbi.nlm.nih.gov/pubmed/31802404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00841-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|